Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Accounts Payables (2016 - 2025)

Moleculin Biotech's Accounts Payables history spans 10 years, with the latest figure at $3.5 million for Q4 2025.

  • Quarterly results put Accounts Payables at $3.5 million for Q4 2025, up 72.81% from a year ago — trailing twelve months through Dec 2025 was $3.5 million (up 72.81% YoY), and the annual figure for FY2025 was $3.5 million, up 72.81%.
  • Accounts Payables for Q4 2025 was $3.5 million at Moleculin Biotech, up from $2.1 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $4.1 million in Q2 2023 to a low of $1.4 million in Q4 2021.
  • The 5-year median for Accounts Payables is $2.2 million (2022), against an average of $2.5 million.
  • The sharpest move saw Accounts Payables skyrocketed 156.69% in 2022, then plummeted 43.72% in 2023.
  • Year by year, Accounts Payables stood at $1.4 million in 2021, then soared by 53.59% to $2.1 million in 2022, then rose by 19.24% to $2.5 million in 2023, then fell by 18.73% to $2.0 million in 2024, then skyrocketed by 72.81% to $3.5 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $3.5 million, $2.1 million, and $3.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.